Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXI NASDAQ:CFRX NASDAQ:OVID NASDAQ:TYME NASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.87+4.1%$0.53$0.17▼$2.90$2.77M-0.07159,614 shs4,728 shsCFRXContraFect$0.05$0.05$0.04▼$13.02$535K0.291.39 million shs910,216 shsOVIDOvid Therapeutics$1.14-10.9%$0.83$0.24▼$1.47$91.02M0.351.37 million shs2.78 million shsTYMETyme Technologies$0.31$0.30$0.22▼$1.14$53.51M0.931.01 million shs2.68 million shsVSTMVerastem$9.13-7.0%$7.45$2.54▼$11.24$604.38M0.932.52 million shs1.85 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics+4.13%-2.14%+52.63%+235.26%-68.82%CFRXContraFect0.00%0.00%0.00%0.00%0.00%OVIDOvid Therapeutics-10.94%-8.06%+17.53%+285.27%-2.56%TYMETyme Technologies0.00%0.00%0.00%0.00%0.00%VSTMVerastem-7.03%-7.96%+11.07%+75.92%+234.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.87+4.1%$0.53$0.17▼$2.90$2.77M-0.07159,614 shs4,728 shsCFRXContraFect$0.05$0.05$0.04▼$13.02$535K0.291.39 million shs910,216 shsOVIDOvid Therapeutics$1.14-10.9%$0.83$0.24▼$1.47$91.02M0.351.37 million shs2.78 million shsTYMETyme Technologies$0.31$0.30$0.22▼$1.14$53.51M0.931.01 million shs2.68 million shsVSTMVerastem$9.13-7.0%$7.45$2.54▼$11.24$604.38M0.932.52 million shs1.85 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics+4.13%-2.14%+52.63%+235.26%-68.82%CFRXContraFect0.00%0.00%0.00%0.00%0.00%OVIDOvid Therapeutics-10.94%-8.06%+17.53%+285.27%-2.56%TYMETyme Technologies0.00%0.00%0.00%0.00%0.00%VSTMVerastem-7.03%-7.96%+11.07%+75.92%+234.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics 0.00N/AN/AN/ACFRXContraFect 0.00N/AN/AN/AOVIDOvid Therapeutics 3.17Buy$3.10171.93% UpsideTYMETyme Technologies 0.00N/AN/AN/AVSTMVerastem 3.00Buy$13.2945.52% UpsideCurrent Analyst Ratings BreakdownLatest CFRX, OVID, TYME, VSTM, and ATXI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025VSTMVerastemBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/25/2025VSTMVerastemB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/12/2025VSTMVerastemZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/8/2025OVIDOvid TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.008/8/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $13.006/25/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$16.00 ➝ $12.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/ACFRXContraFectN/AN/AN/AN/A($19.92) per shareN/AOVIDOvid Therapeutics$570K142.22N/AN/A$0.96 per share1.19TYMETyme TechnologiesN/AN/AN/AN/A$0.47 per shareN/AVSTMVerastem$10K56,186.02N/AN/A($0.65) per share-14.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M-$0.950.05∞N/AN/A-471.57%-296.50%11/12/2025 (Estimated)CFRXContraFect-$65.15M-$19.27N/AN/AN/AN/AN/A-138.70%N/AOVIDOvid Therapeutics-$26.43M-$0.53N/AN/AN/A-574.44%-58.87%-43.18%11/11/2025 (Estimated)TYMETyme Technologies-$23.63M-$0.14N/A∞N/AN/A-28.30%-26.21%N/AVSTMVerastem-$130.64M-$3.28N/AN/AN/AN/A-2,003.62%-119.85%11/5/2025 (Estimated)Latest CFRX, OVID, TYME, VSTM, and ATXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025OVIDOvid Therapeutics-$0.16-$0.06+$0.10-$0.06$0.09 million$6.27 million8/7/2025Q2 2025VSTMVerastem-$0.64-$0.39+$0.25-$0.39$6.01 million$2.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/ACFRXContraFectN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ATYMETyme TechnologiesN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A2.702.70CFRXContraFectN/A0.530.53OVIDOvid Therapeutics0.234.724.72TYMETyme TechnologiesN/A14.0614.06VSTMVerastem2.063.463.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%CFRXContraFect7.85%OVIDOvid Therapeutics72.24%TYMETyme Technologies16.69%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics1.80%CFRXContraFect0.62%OVIDOvid Therapeutics13.10%TYMETyme Technologies16.90%VSTMVerastem2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics43.18 million2.02 millionNot OptionableCFRXContraFect2310.70 million10.64 millionNot OptionableOVIDOvid Therapeutics6071.11 million61.80 millionOptionableTYMETyme Technologies17172.21 million143.10 millionOptionableVSTMVerastem5061.54 million60.25 millionOptionableCFRX, OVID, TYME, VSTM, and ATXI HeadlinesRecent News About These CompaniesTop Biotech Picks for 2025: BTIG Research Highlights Potential WinnersSeptember 16 at 4:52 PM | finance.yahoo.comVerastem (NASDAQ:VSTM) Lowered to Sell Rating by Wall Street ZenSeptember 15 at 2:07 AM | marketbeat.comVerastem (NASDAQ:VSTM) Lowered to "Sell" Rating by Wall Street ZenSeptember 14 at 3:55 AM | americanbankingnews.comVerastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Buy" by AnalystsSeptember 13, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Trading Down 7.6% - Should You Sell?September 12, 2025 | marketbeat.comBTIG Research Reaffirms Buy Rating for Verastem (NASDAQ:VSTM)September 11, 2025 | marketbeat.comOctagon Capital Advisors LP Invests $10.37 Million in Verastem, Inc. $VSTMSeptember 11, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Earns "Buy" Rating from BTIG ResearchSeptember 11, 2025 | americanbankingnews.comVerastem’s Promising KRAS G12D Inhibitor VS-7375: A Buy Rating Backed by Strong Clinical Data and Strategic OutlookSeptember 9, 2025 | tipranks.comPolar Asset Management Partners Inc. Invests $300,000 in Verastem, Inc. $VSTMSeptember 9, 2025 | marketbeat.comLeerink says competitor data suggest promising view for Revolution’s zoldonrasibSeptember 8, 2025 | msn.comVerastem Updates on Cancer Therapy DevelopmentsSeptember 8, 2025 | tipranks.comNuveen LLC Makes New Investment in Verastem, Inc. $VSTMSeptember 8, 2025 | marketbeat.comNomura Holdings Inc. Invests $1.26 Million in Verastem, Inc. $VSTMSeptember 6, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Hits New 1-Year High - Should You Buy?September 5, 2025 | marketbeat.comNantahala Capital Management LLC Sells 1,454,042 Shares of Verastem, Inc. $VSTMSeptember 3, 2025 | marketbeat.comWellington Management Group LLP Takes Position in Verastem, Inc. $VSTMSeptember 2, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Sets New 1-Year High - What's Next?August 30, 2025 | marketbeat.comB. Riley Upgrades Verastem (NASDAQ:VSTM) to Strong-BuyAugust 29, 2025 | marketbeat.comVerastem Oncology to Present at Upcoming Investor ConferencesAugust 27, 2025 | mms.businesswire.comVerastem, Inc. $VSTM Shares Sold by Stonepine Capital Management LLCAugust 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGrab Holdings: Get a Grip Now—Explosive Upside Brewing By Thomas Hughes | August 18, 2025Small Cap, Big Potential: 3 Tech Disruptors You Should Know AboutBy Nathan Reiff | August 22, 2025Is It Too Late to Jump on the Nuclear Bandwagon? By Jordan Chussler | August 25, 2025AI Exposure Without the Hype: 3 ETFs That Offer Smarter AI BetsBy Nathan Reiff | August 25, 2025What August Labor Data Means for the S&P 500 in SeptemberBy Thomas Hughes | September 8, 2025CFRX, OVID, TYME, VSTM, and ATXI Company DescriptionsAvenue Therapeutics NASDAQ:ATXI$0.87 +0.03 (+4.13%) As of 09/16/2025 03:47 PM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.ContraFect NASDAQ:CFRXContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.Ovid Therapeutics NASDAQ:OVID$1.14 -0.14 (-10.94%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$1.16 +0.02 (+2.11%) As of 05:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Tyme Technologies NASDAQ:TYMETyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.Verastem NASDAQ:VSTM$9.13 -0.69 (-7.03%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$9.26 +0.13 (+1.42%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
